Search

Bridging the Gap Between Science and Communities

In a moment when access to clear, credible HIV science has never been more urgent, AVAC is bridging the gap between global research conferences and the communities who need that information most—through real-time webinars, digestible recaps, and resources trusted by leading researchers.

Standing Up for Science

As the US administration threatens to dismantle decades of biomedical research progress, AVAC and partners have mounted a powerful defense—highlighted by the 24-Hour Marathon to Save AIDS Research, which united 75 presenters and reached more than 7,000 people across 28 countries.

Strengthening Access Planning

Zambia made history on World AIDS Day 2025 by becoming one of the first African countries to launch lenacapavir—just 18 months after pivotal trial results were announced. This milestone reflects years of coordinated advocacy, community engagement, and technical support that’s setting a new standard for speed and equity in HIV prevention rollouts globally.

AVAC Roundup: Must-See Resources from the Last Week 

From spotlighting the impact of US-supported HIV research to advancing the future of the HIV response; accelerating pediatric HIV cure research to shaping the global STI agenda, AVAC is driving and tracking the critical conversations defining HIV prevention and advocacy. Read on for this week’s resources and perspectives.

Opportunities, Controversies & Cruel Ironies

View the slides from AVAC Executive Director Mitchell Warren plenary presentation at SYNChronicity 2026.

Global Health Watch: Court Blocks ACIP Overhaul, NIH Director Promises to Disburse Funds, State Dept Pulls “America First” Health MoUs

A US federal court blocked the US Administration’s efforts to overhaul the CDC’s Advisory Committee on Immunization Practices, while the NIH Director sought to reassure lawmakers over funding delays and shifting research priorities. Meanwhile, the State Department quietly removed five “America First” health agreements from public access as scrutiny grows, and Argentina announced its intent to withdraw from the WHO.

The Power of bNAbs: A new frontier in HIV cure research

In this video, from the Series of Jojo, viewers are introduced to broadly neutralizing antibodies (bNAbs) and how they might one day be used in finding a functional cure for HIV.

EXPrESSIVE Phase III Program Countries of MK-8527

Seventeen countries are hosting sites for the Phase 3 efficacy trials of a monthly PrEP pill, MK-8527, being developed by Merck (also known as MSD outside of the US and Canada). Merck announced the launch of the Phase 3 trials at IAS 2025 in Kigali. MK-8527 was found to be safe and well-tolerated in Phase 2 clinical trials.

Launching STI Advocacy Hubs: National Agendas from Kenya, South Africa & Zimbabwe

The Benefits To Americans Of US-Supported International HIV Research

A new Health Affairs piece by Judith Auerbach, Jirair Ratevosian, and AVAC’s Mitchell Warren makes the case that cuts to US-supported global HIV research don’t just hurt partner countries. They undermine the scientific pipeline that delivers those advances to Americans most in need. As the Trump administration scales back global health investments, the US risks squandering decades of research returns just as they’re beginning to pay off.